JP2019520063A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2019520063A5 JP2019520063A5 JP2018562201A JP2018562201A JP2019520063A5 JP 2019520063 A5 JP2019520063 A5 JP 2019520063A5 JP 2018562201 A JP2018562201 A JP 2018562201A JP 2018562201 A JP2018562201 A JP 2018562201A JP 2019520063 A5 JP2019520063 A5 JP 2019520063A5
- Authority
- JP
- Japan
- Prior art keywords
- antibody
- human
- binds
- positions
- pair
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2021184049A JP2022010244A (ja) | 2016-05-26 | 2021-11-11 | 抗体の混合物 |
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201662342167P | 2016-05-26 | 2016-05-26 | |
| US62/342,167 | 2016-05-26 | ||
| PCT/US2017/030676 WO2017205014A1 (en) | 2016-05-26 | 2017-05-02 | Mixtures of antibodies |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2021184049A Division JP2022010244A (ja) | 2016-05-26 | 2021-11-11 | 抗体の混合物 |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2019520063A JP2019520063A (ja) | 2019-07-18 |
| JP2019520063A5 true JP2019520063A5 (enExample) | 2020-06-18 |
| JP7301540B2 JP7301540B2 (ja) | 2023-07-03 |
Family
ID=58709577
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2018562201A Active JP7301540B2 (ja) | 2016-05-26 | 2017-05-02 | 抗体の混合物 |
| JP2021184049A Withdrawn JP2022010244A (ja) | 2016-05-26 | 2021-11-11 | 抗体の混合物 |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2021184049A Withdrawn JP2022010244A (ja) | 2016-05-26 | 2021-11-11 | 抗体の混合物 |
Country Status (7)
| Country | Link |
|---|---|
| US (2) | US11130808B2 (enExample) |
| EP (1) | EP3463451A1 (enExample) |
| JP (2) | JP7301540B2 (enExample) |
| CN (1) | CN109475627B (enExample) |
| AU (1) | AU2017269115B2 (enExample) |
| CA (1) | CA3025162A1 (enExample) |
| WO (1) | WO2017205014A1 (enExample) |
Families Citing this family (43)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| TR201802772T4 (tr) | 2010-11-17 | 2018-03-21 | Chugai Pharmaceutical Co Ltd | Kan pıhtılaşma faktörü VIII in işlevi için alternatif işleve sahip multi-spesifik antijen bağlayıcı molekül. |
| LT2647707T (lt) | 2010-11-30 | 2018-11-12 | Chugai Seiyaku Kabushiki Kaisha | Citotoksiškumą indukuojantis terapinis agentas |
| US11851476B2 (en) | 2011-10-31 | 2023-12-26 | Chugai Seiyaku Kabushiki Kaisha | Antigen-binding molecule having regulated conjugation between heavy-chain and light-chain |
| JP6954842B2 (ja) | 2015-12-25 | 2021-10-27 | 中外製薬株式会社 | 増強された活性を有する抗体及びその改変方法 |
| JP7320943B2 (ja) | 2016-04-28 | 2023-08-04 | 中外製薬株式会社 | 抗体含有製剤 |
| CA3037380A1 (en) | 2016-10-11 | 2018-04-19 | Agenus Inc. | Anti-lag-3 antibodies and methods of use thereof |
| TW201834688A (zh) * | 2017-02-24 | 2018-10-01 | 日商中外製藥股份有限公司 | 藥學組成物、抗原結合分子、治療方法以及篩選方法 |
| EP3431105B1 (en) | 2017-03-29 | 2020-01-01 | Shionogi&Co., Ltd. | Medicinal composition for treating cancer |
| UA128389C2 (uk) * | 2017-09-29 | 2024-07-03 | Чугаі Сейяку Кабусікі Кайся | Мультиспецифічна антигензв'язувальна молекула, яка має активність заміщувати кофакторну функцію фактора коагуляції крові viii (fviii), та фармацевтичний склад, який містить згадану молекулу як активний інгредієнт |
| AU2018361430B2 (en) | 2017-11-01 | 2025-08-14 | Chugai Seiyaku Kabushiki Kaisha | Antibody variant and isoform with lowered biological activity |
| WO2019107384A1 (ja) | 2017-11-28 | 2019-06-06 | 中外製薬株式会社 | リガンド結合活性が調整可能なリガンド結合分子 |
| JP2019151621A (ja) * | 2018-02-28 | 2019-09-12 | 学校法人藤田学園 | Ｋａｔ阻害活性を有する化合物を含有するがん治療用組成物 |
| CN110357960A (zh) * | 2018-04-10 | 2019-10-22 | 广州爱思迈生物医药科技有限公司 | 抗体及抗体改造方法 |
| US11591390B2 (en) | 2018-09-27 | 2023-02-28 | Celgene Corporation | SIRP-α binding proteins and methods of use thereof |
| BR112021005585A2 (pt) | 2018-09-27 | 2021-06-29 | Celgene Corporation | proteínas de ligação a sirpa e métodos de uso das mesmas |
| WO2020180811A1 (en) | 2019-03-04 | 2020-09-10 | Qilu Puget Sound Biotherapeutics Corporation | Anti-sirp-alpha antibodies |
| CN110551221B (zh) * | 2019-07-02 | 2021-03-05 | 广州爱思迈生物医药科技有限公司 | 一种双特异性抗体及其制备方法与应用 |
| AU2020336440A1 (en) | 2019-08-30 | 2022-03-24 | Qilu Puget Sound Biotherapeutics Corporation | Anti-CD20 antibodies, anti-CD37 antibodies, and mixtures thereof |
| US20230265134A1 (en) * | 2019-09-30 | 2023-08-24 | Adimab, Llc | Ch1 domain variants engineered for preferential light chain pairing and multispecific antibodies comprising the same |
| WO2021126538A1 (en) * | 2019-12-17 | 2021-06-24 | Phanes Therapeutics, Inc. | Bispecific antibodies with alternatively matched interchain cycteines and uses thereof |
| EP4093875A4 (en) * | 2020-01-20 | 2024-02-28 | Chugai Seiyaku Kabushiki Kaisha | Ligand-binding fusion proteins |
| CA3170741A1 (en) * | 2020-07-31 | 2022-02-03 | Curevac Ag | Nucleic acid encoded antibody mixtures |
| EP4200338A1 (en) * | 2020-08-20 | 2023-06-28 | Amgen Inc. | Antigen binding proteins with non-canonical disulfide in fab region |
| MX2023002511A (es) * | 2020-08-28 | 2023-04-20 | Harbour Biomed Us Inc | Anticuerpo anti-ccr8 y aplicacion del mismo. |
| CN114437226A (zh) * | 2020-11-05 | 2022-05-06 | 杭州菁因康生物科技有限公司 | 制备双特异性抗体的方法 |
| EP4294531A4 (en) * | 2021-02-18 | 2025-07-16 | Qilu Puget Sound Biotherapeutics Corp | COMBINATIONS OF ANTI-PD1 AND ANTI-CTLA4 ANTIBODIES |
| CN112961245B (zh) * | 2021-02-24 | 2023-07-25 | 重庆精准生物技术有限公司 | 一种靶向cd96的双特异性抗体及其制备方法和用途 |
| MX2023012324A (es) * | 2021-04-20 | 2023-10-30 | Amgen Inc | Distribucion de carga equilibrada en una direccion electrostatica del emparejamiento de cadenas en el conjunto de moleculas de igg multiespecificas y monovalentes. |
| US20240182576A1 (en) * | 2021-04-23 | 2024-06-06 | Chimagen Biosciences, Ltd | Heterodimeric antibodies and antigen-binding fragment thereof |
| US20230048743A1 (en) * | 2021-07-12 | 2023-02-16 | Genentech Inc. | Structures for Reducing Antibody-Lipase Binding |
| IL309856A (en) | 2021-07-14 | 2024-02-01 | Genentech Inc | Antibodies anti-C-C motif receptor 8 (CCR8) and methods of use |
| JP2024527582A (ja) * | 2021-07-19 | 2024-07-25 | 中外製薬株式会社 | 融合ポリペプチドを用いるプロテアーゼ媒介性の標的特異的サイトカイン送達 |
| CN118339188A (zh) * | 2021-09-21 | 2024-07-12 | 齐鲁普吉湾生物治疗公司 | 用于制备融合蛋白和双特异性抗体的异二聚体Fc |
| CN118660720A (zh) * | 2022-02-22 | 2024-09-17 | 齐鲁制药有限公司 | 包含抗ctla4和抗pd1的混合抗体的药物组合物及其治疗用途 |
| CN118946366A (zh) * | 2022-04-13 | 2024-11-12 | 齐鲁制药有限公司 | 包含抗ctla4和抗pd1的混合抗体的药物组合物及其治疗用途 |
| CN119300862A (zh) * | 2022-06-28 | 2025-01-10 | 齐鲁制药有限公司 | 包含抗ctla4和抗pd1的混合抗体的药物组合物及其治疗用途 |
| CN119300863A (zh) * | 2022-06-30 | 2025-01-10 | 齐鲁制药有限公司 | 包含抗ctla4和抗pd1的混合抗体的药物组合物及其治疗用途 |
| CN119604525A (zh) | 2022-07-22 | 2025-03-11 | 信达生物制药(苏州)有限公司 | 促进多特异性抗体的重链和轻链同源配对的突变体 |
| EP4644548A1 (en) | 2022-12-27 | 2025-11-05 | Chugai Seiyaku Kabushiki Kaisha | Polypeptide with controlled association |
| EP4655595A1 (en) * | 2023-01-25 | 2025-12-03 | Regeneron Pharmaceuticals, Inc. | Mass spectrometry-based characterization of antibodies co-expressed in vivo |
| WO2025059037A1 (en) * | 2023-09-11 | 2025-03-20 | Evolveimmune Therapeutics, Inc. | Bispecific antibody fusion molecules targeting b7-h4 and cd3 and methods of use thereof |
| WO2025117485A1 (en) * | 2023-11-29 | 2025-06-05 | Qilu Puget Sound Biotherapeutics Corporation | Anti-il33 and anti-tslp antibodies, and mixtures |
| WO2025228542A1 (en) | 2024-05-03 | 2025-11-06 | Genmab B.V. | Method for co-expression of a plurality of antibodies |
Family Cites Families (30)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5731168A (en) | 1995-03-01 | 1998-03-24 | Genentech, Inc. | Method for making heteromultimeric polypeptides |
| SI1523496T1 (sl) | 2002-07-18 | 2011-11-30 | Merus B V | Rekombinantno proizvajanje zmesi protiteles |
| CA2512647C (en) * | 2003-01-07 | 2013-10-08 | Symphogen A/S | Method for manufacturing recombinant polyclonal proteins |
| GB0514779D0 (en) | 2005-07-19 | 2005-08-24 | Celltech R&D Ltd | Biological products |
| WO2007147901A1 (en) | 2006-06-22 | 2007-12-27 | Novo Nordisk A/S | Production of bispecific antibodies |
| PL2132229T3 (pl) * | 2007-03-01 | 2016-12-30 | Kompozycje rekombinowanych przeciwciał anty-receptor czynnika wzrostu naskórka | |
| WO2008145142A1 (en) | 2007-05-31 | 2008-12-04 | Genmab A/S | Stable igg4 antibodies |
| PT2235064E (pt) * | 2008-01-07 | 2016-03-01 | Amgen Inc | Método de preparação de moléculas heterodiméricas de fc de anticorpos utilizando efeitos de indução eletrostática |
| EP3153524B1 (en) | 2008-12-03 | 2025-04-23 | Genmab A/S | Antibody variants having modifications in the constant region |
| CN102365296A (zh) * | 2009-01-26 | 2012-02-29 | 根马布股份公司 | 用于生成抗体混合物的方法 |
| WO2011109726A2 (en) * | 2010-03-05 | 2011-09-09 | Bioatla Llc | Homologous multi-specific antibodies |
| US20130177555A1 (en) | 2010-08-13 | 2013-07-11 | Medimmune Limited | Monomeric Polypeptides Comprising Variant FC Regions And Methods Of Use |
| EP2686682A4 (en) | 2011-03-11 | 2015-03-11 | Amgen Inc | METHOD FOR CORRELATED MUTATION ANALYSIS TO IMPROVE THERAPEUTIC ANTIBODIES |
| MX348071B (es) | 2011-03-16 | 2017-05-26 | Amgen Inc | Variantes de fc. |
| BR112013023653A2 (pt) | 2011-03-17 | 2016-12-13 | Univ Ramot | anticorpo biespecífico, método de preparação do anticorpo, e composição farmacêutica |
| SG11201401422VA (en) | 2011-10-27 | 2014-09-26 | Genmab As | Production of heterodimeric proteins |
| PL2794905T3 (pl) * | 2011-12-20 | 2020-11-02 | Medimmune, Llc | Zmodyfikowane polipeptydy dla rusztowań przeciwciał dwuswoistych |
| ES2743399T3 (es) | 2012-04-20 | 2020-02-19 | Merus Nv | Métodos y medios para la producción de moléculas heterodiméricas similares a Ig |
| CA2872540A1 (en) | 2012-05-10 | 2013-11-14 | Zymeworks Inc. | Heteromultimer constructs of immunoglobulin heavy chains with mutations in the fc domain |
| CN102851338A (zh) | 2012-07-25 | 2013-01-02 | 苏州康宁杰瑞生物科技有限公司 | 利用电荷排斥作用制备同二聚体蛋白混合物的方法 |
| CN110669136A (zh) * | 2012-11-05 | 2020-01-10 | 全药工业株式会社 | 抗体或抗体组合物的制备方法 |
| UY35148A (es) | 2012-11-21 | 2014-05-30 | Amgen Inc | Immunoglobulinas heterodiméricas |
| DK2927321T3 (da) | 2012-11-27 | 2021-03-15 | Univ Ajou Ind Academic Coop Found | Ch3-domæne-variantpar der inducerer dannelse af heterodimer af tungkæde konstant region af antistof ved høj effektivitet, fremgangsmåde til fremstilling af samme, og anvendelse deraf |
| KR102545617B1 (ko) | 2012-11-28 | 2023-06-20 | 자임워크스 비씨 인코포레이티드 | 가공된 면역글로불린 중쇄-경쇄 쌍 및 이들의 용도 |
| KR101813708B1 (ko) | 2013-03-13 | 2017-12-29 | (주) 아이벤트러스 | 소수성 상호작용 부위내에 전기적 상호작용이 도입된 단백질 및 이의 제조방법 |
| EP2970435B1 (en) | 2013-03-15 | 2020-08-12 | Eli Lilly and Company | Methods for producing fabs and bi-specific antibodies |
| KR20250152665A (ko) | 2013-07-31 | 2025-10-23 | 암젠 인크 | Ｆc-함유 폴리펩타이드의 안정화 |
| US10684289B2 (en) | 2013-12-09 | 2020-06-16 | Adimab, Llc | Polyclonal mixtures of antibodies, and methods of making and using them |
| EP3143043B1 (en) * | 2014-05-16 | 2022-12-14 | Pfizer Inc. | Bispecific antibodies with engineered ch1-cl interfaces |
| AU2017356860A1 (en) * | 2016-11-08 | 2019-05-16 | Qilu Puget Sound Biotherapeutics Corporation | Anti-PD1 and anti-CTLA4 antibodies |
-
2017
- 2017-05-02 CA CA3025162A patent/CA3025162A1/en active Pending
- 2017-05-02 CN CN201780043870.9A patent/CN109475627B/zh active Active
- 2017-05-02 AU AU2017269115A patent/AU2017269115B2/en not_active Expired - Fee Related
- 2017-05-02 WO PCT/US2017/030676 patent/WO2017205014A1/en not_active Ceased
- 2017-05-02 EP EP17723832.6A patent/EP3463451A1/en active Pending
- 2017-05-02 JP JP2018562201A patent/JP7301540B2/ja active Active
- 2017-05-05 US US16/303,611 patent/US11130808B2/en active Active
-
2021
- 2021-09-23 US US17/483,630 patent/US20220073615A1/en active Pending
- 2021-11-11 JP JP2021184049A patent/JP2022010244A/ja not_active Withdrawn